The lack of available organs for liver transplantation (LT) associated with the
increased death rates among patients on the waiting lists for LT has triggered
the use of so-called extended criteria donor (ECD) grafts. Among the wide range
of these ECD livers, hepatic steatosis is one of the most frequent disorders,
which is mostly related to an increasing prevalence of non-alcoholic fatty liver
disease (NAFLD). NAFLD is increasingly significant in healthy individuals for its
high worldwide prevalence, an association with the metabolic syndrome, such
as insulin resistance, diabetes, dyslipidemia and obesity, and an association with
liver-related morbidity and mortality. Using the ECD grafts especially those with
NAFLD will markedly increase the donor pool for LT. Several approaches, including
long-term and short-term measures, were identified for the management of
NAFLD.